• Je něco špatně v tomto záznamu ?

An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA)

J. Carles, A. Pichler, H. Korunkova, A. Tomova, M. Ghosn, F. El Karak, J. Makdessi, I. Koroleva, G. Barnes, D. Bury, A. Özatilgan, S. Hitier, J. Katolicka,

. 2019 ; 123 (3) : 456-464. [pub] 20180916

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045312

OBJECTIVES: To obtain routine clinical practice data on cabazitaxel usage patterns for patients with metastatic castration-resistant prostate cancer (mCRPC) and to describe physician-assessed cabazitaxel effectiveness, health-related quality of life (HRQoL) and safety. PATIENTS AND METHODS: CAPRISTANA was an international, observational cohort study examining cabazitaxel use for the treatment of patients with mCRPC. Effectiveness was assessed by overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF) and disease control rate. HRQoL was assessed using the Functional Assessment of Cancer Therapy-Prostate questionnaire (FACT-P) and the three-level European Quality of Life questionnaire (EQ-5D-3L). Safety was assessed by adverse event (AE) reporting. RESULTS: A total of 189 patients were treated across 54 centres between April 2012 and June 2016. At baseline, 58.7% had ≥1 comorbidity, 93.7% had an Eastern Cooperative Oncology Group performance status ≤1, and 60.1% had a Gleason score at diagnosis of ≥8. Patients received a median of 6 cabazitaxel cycles; 84.7% received cabazitaxel as second-line therapy. The median OS, PFS and TTF were 13.2, 5.6 and 4.4 months, respectively. Cabazitaxel led to disease control in 52.9% of patients. HRQoL was maintained (40.3%) or improved (32.2%) in 72.5% of patients based on total FACT-P scores. Interestingly, 53.6% of patients reported pain improvement and a further 21.2% maintained pain control based on FACT-P prostate cancer-specific pain scores. The most common treatment-related grade ≥3 AEs were neutropenia (7.9%) and anaemia (2.1%). CONCLUSION: Patients in CAPRISTANA treated with cabazitaxel had similar disease outcomes and safety profiles compared with large phase III clinical trials. Most patients had maintained or improved HRQoL scores; >70% of patients had maintained or improved pain control.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045312
003      
CZ-PrNML
005      
20200113085458.0
007      
ta
008      
200109s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bju.14509 $2 doi
035    __
$a (PubMed)30098093
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Carles, Joan $u Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
245    13
$a An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA) / $c J. Carles, A. Pichler, H. Korunkova, A. Tomova, M. Ghosn, F. El Karak, J. Makdessi, I. Koroleva, G. Barnes, D. Bury, A. Özatilgan, S. Hitier, J. Katolicka,
520    9_
$a OBJECTIVES: To obtain routine clinical practice data on cabazitaxel usage patterns for patients with metastatic castration-resistant prostate cancer (mCRPC) and to describe physician-assessed cabazitaxel effectiveness, health-related quality of life (HRQoL) and safety. PATIENTS AND METHODS: CAPRISTANA was an international, observational cohort study examining cabazitaxel use for the treatment of patients with mCRPC. Effectiveness was assessed by overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF) and disease control rate. HRQoL was assessed using the Functional Assessment of Cancer Therapy-Prostate questionnaire (FACT-P) and the three-level European Quality of Life questionnaire (EQ-5D-3L). Safety was assessed by adverse event (AE) reporting. RESULTS: A total of 189 patients were treated across 54 centres between April 2012 and June 2016. At baseline, 58.7% had ≥1 comorbidity, 93.7% had an Eastern Cooperative Oncology Group performance status ≤1, and 60.1% had a Gleason score at diagnosis of ≥8. Patients received a median of 6 cabazitaxel cycles; 84.7% received cabazitaxel as second-line therapy. The median OS, PFS and TTF were 13.2, 5.6 and 4.4 months, respectively. Cabazitaxel led to disease control in 52.9% of patients. HRQoL was maintained (40.3%) or improved (32.2%) in 72.5% of patients based on total FACT-P scores. Interestingly, 53.6% of patients reported pain improvement and a further 21.2% maintained pain control based on FACT-P prostate cancer-specific pain scores. The most common treatment-related grade ≥3 AEs were neutropenia (7.9%) and anaemia (2.1%). CONCLUSION: Patients in CAPRISTANA treated with cabazitaxel had similar disease outcomes and safety profiles compared with large phase III clinical trials. Most patients had maintained or improved HRQoL scores; >70% of patients had maintained or improved pain control.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a protokoly protinádorové kombinované chemoterapie $7 D000971
650    _2
$a docetaxel $x škodlivé účinky $x terapeutické užití $7 D000077143
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neutrofily $x účinky léků $7 D009504
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a nádory prostaty rezistentní na kastraci $x farmakoterapie $x mortalita $x patologie $7 D064129
650    _2
$a kvalita života $7 D011788
650    _2
$a míra přežití $7 D015996
650    _2
$a taxoidy $x terapeutické užití $7 D043823
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pichler, Angelika $u Department of Hematology and Oncology, Landeskrankenhaus Hochsteiermark, Leoben, Austria.
700    1_
$a Korunkova, Hana $u Department of Oncology and Radiotherapy, University Hospital, Plzen, Czech Republic.
700    1_
$a Tomova, Antoaneta $u Department of Oncology, Complex Oncology Center, Plovdiv, Bulgaria.
700    1_
$a Ghosn, Marwan $u Department of Hematology and Oncology, Hotel Dieu de France University Hospital, Saint Joseph University, Beirut, Lebanon.
700    1_
$a El Karak, Fadi $u Department of Hematology and Oncology, Hotel Dieu de France University Hospital, Saint Joseph University, Beirut, Lebanon.
700    1_
$a Makdessi, Joseph $u Department of Medicine, St. George Hospital, Beirut, Lebanon.
700    1_
$a Koroleva, Irina $u Department of Medicine, Medical University "Reaviz", Samara, Russia.
700    1_
$a Barnes, Gisoo $u Department of Clinical Outcomes, Sanofi, Cambridge, MA, USA.
700    1_
$a Bury, Denise $u Department of Clinical Outcomes, Sanofi, Cambridge, MA, USA.
700    1_
$a Özatilgan, Ayse $u Global Medical Affairs Oncology, Sanofi, Cambridge, MA, USA.
700    1_
$a Hitier, Simon $u Department of Biostatistics, Sanofi, Chilly-Mazarin, France.
700    1_
$a Katolicka, Jana $u Department of Oncology, St. Ann's University Hospital, Brno, Czech Republic.
773    0_
$w MED00011371 $t BJU international $x 1464-410X $g Roč. 123, č. 3 (2019), s. 456-464
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30098093 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113085830 $b ABA008
999    __
$a ok $b bmc $g 1483581 $s 1083985
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 123 $c 3 $d 456-464 $e 20180916 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace